10 Triumphant Drug Launches Of The Decade
The view from 2020: Scrip looks back at the most successful commercial launches of the decade.
You may also be interested in...
The companies’ third vaccine-development deal shows how COVID cash has also led mRNA-focused companies to beef up their organic pipelines amid talk of a merger wave.
Pfizer said it expects to generate $26bn in annual revenues from the COVID-19 vaccine BNT162b2 and is leveraging the platform to build out a durable business.
The company still plans to file 20vPnC for US FDA approval by the end of 2020 after the pneumococcal vaccine was non-inferior to Prevnar and to Pneumovax on six additional serotypes in older patients.